Skip to content
Comparison

Orforglipron vs Tirzepatide (Zepbound)

Orforglipron is an investigational oral GLP-1 receptor agonist (small molecule, non-peptide) developed by Eli Lilly, currently in Phase 3 clinical trials. Tirzepatide (Zepbound) is a FDA-approved weekly injectable dual GIP/GLP-1 receptor agonist with an established efficacy record. As of early 2026, orforglipron has demonstrated approximately 9–14.7% weight loss in Phase 2 trials — impressive for a once-daily pill but still below tirzepatide's 20–22.5%. Orforglipron's key advantage is oral administration with no injection required, no food restrictions (unlike oral semaglutide which requires fasting), and lower projected cost. Tirzepatide remains the efficacy leader, but orforglipron may become the access leader upon approval.

4.3(112 ratings)

Quick Answer

Orforglipron (oral GLP-1 pill, in Phase 3 trials as of 2026) vs tirzepatide (Zepbound, FDA-approved weekly injection): orforglipron produces ~9–14.7% weight loss (Phase 2 data) vs tirzepatide's ~20–22.5%, but orforglipron requires no injection and no fasting — a significant access and convenience advantage. Tirzepatide currently leads on efficacy; orforglipron may close the gap in Phase 3 and could dramatically expand the population willing to take GLP-1 therapy if approved.

Head-to-Head Comparison

CriteriaOrforglipronTirzepatide (Zepbound)
Drug classSmall-molecule oral GLP-1 receptor agonist (non-peptide, peptidomimetic)Injectable dual GIP/GLP-1 receptor agonist peptide ("twincretin")
Route & frequencyOnce daily oral tablet — no injection, no fasting required (unlike oral semaglutide)Once weekly subcutaneous injection
FDA approval status (2026)Investigational — Phase 3 trials ongoing (ATTAIN program); not yet approvedFDA-approved: Zepbound (obesity, Nov 2023); Mounjaro (T2D, May 2022); OSA (Dec 2024)
Weight loss (best available data)~9–14.7% body weight in Phase 2 trials (GZGI study at highest dose, 36 weeks)~20–22.5% body weight (SURMOUNT-1, Phase 3, highest dose, 88 weeks)
A1C reduction (T2D)~1.3–2.1% in Phase 2 T2D trials~2.0–2.3% (SURPASS program)
Food requirementNo fasting required — significant advantage over oral semaglutide (Rybelsus)No food restrictions for injections
Nausea incidence~26–33% in Phase 2 — comparable to injectables~31% in SURMOUNT-1 at highest dose
Projected cost (estimate)Not yet priced; analysts project competitive pricing vs injectables (~$500–$900/month)~$1,060–$1,200/month (Zepbound list price)
Cardiovascular outcomesNo completed CV outcomes trial; Phase 3 includes CV endpointsSURMOUNT-CVOT ongoing; secondary positive endpoints in trial program
Mechanism advantageOral small molecule — avoids injection barriers; may reach larger patient populationDual incretin (GIP + GLP-1) — additive efficacy beyond GLP-1 alone
Competitive vs oral semaglutideSuperior to oral semaglutide: no fasting, potentially more weight lossN/A — injectable vs oral comparison

When to Choose Each

Choose Orforglipron

Patients who are injection-averse or cannot self-administer weekly injections, those seeking a simpler oral pill regimen, patients in markets where injectable GLP-1s are cost-prohibitive, and anyone willing to accept somewhat lower efficacy for oral convenience. (Note: not yet FDA-approved as of Feb 2026.)

Choose Tirzepatide (Zepbound)

Anyone who can tolerate weekly self-injection and wants maximum FDA-approved weight loss efficacy, patients with obstructive sleep apnea and obesity (unique Zepbound indication), and anyone who needs an established drug with full Phase 3 safety data.

Verdict

Tirzepatide (Zepbound) currently leads on efficacy — its ~20–22.5% weight loss from Phase 3 trials is the best documented of any approved anti-obesity medication as of 2026. Orforglipron's Phase 2 data (~9–14.7% weight loss) is promising for an oral drug, but meaningfully lower than tirzepatide. That said, orforglipron's potential impact on the obesity treatment landscape is large: if Phase 3 confirms Phase 2 results and FDA approval follows, an effective once-daily pill without fasting requirements could reach millions of patients who are unwilling or unable to self-inject weekly. Eli Lilly is investing heavily in orforglipron as the next oral GLP-1 platform. For patients who can inject and want maximum efficacy today, tirzepatide is the clear choice. If oral convenience is paramount, watch for orforglipron Phase 3 readouts expected in 2025–2026.

References

  1. Orforglipron (LY3502970): a GLP-1 receptor agonist for type 2 diabetes (Phase 2, GZGI study) (2023) — PubMed
  2. Oral GLP-1 receptor agonists: orforglipron Phase 2 efficacy for obesity (2024) — PubMed
  3. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
  4. Oral semaglutide versus subcutaneous semaglutide in type 2 diabetes (PIONEER 4) (2019) — PubMed
  5. GIP and GLP-1 as incretin hormones: lessons from single and dual incretin receptor knockouts in mice (2023) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Is orforglipron FDA-approved?
No — as of February 2026, orforglipron is not FDA-approved. It is in Phase 3 clinical trials (the ATTAIN program for obesity and ATTAIN-T2D for type 2 diabetes). Phase 3 readouts are expected in 2025–2026. If trials succeed and FDA review proceeds normally, approval could potentially come in 2026–2027. Orforglipron is manufactured by Eli Lilly, the same company as tirzepatide/Zepbound/Mounjaro.
How is orforglipron different from oral semaglutide (Rybelsus)?
Key differences: (1) Orforglipron requires no fasting — Rybelsus requires a 30-minute fasting period before dosing with limited water, which creates compliance challenges. (2) Orforglipron is a small-molecule GLP-1 agonist (not a peptide), so it is fully orally bioavailable without special formulation. (3) Phase 2 data suggests orforglipron produces more weight loss than Rybelsus (9–14.7% vs ~5–8% for oral semaglutide at approved T2D doses). If approved for obesity, orforglipron could substantially outperform Rybelsus for weight management.
How does orforglipron compare to tirzepatide for weight loss?
Tirzepatide currently produces more weight loss. Phase 2 orforglipron data shows ~9–14.7% body weight loss (GZGI study); Phase 3 tirzepatide data shows ~20–22.5% (SURMOUNT-1). The gap is approximately 7–10 percentage points. However, Phase 2 data often underestimates Phase 3 results due to lower doses and shorter follow-up. Phase 3 orforglipron data at higher doses over longer follow-up periods may narrow this gap. Tirzepatide also adds GIP receptor activation that orforglipron lacks.
When will orforglipron be available?
If Phase 3 trials succeed, Eli Lilly has stated it could file for FDA approval in 2026. Assuming standard FDA review timelines of 6–12 months, approval could potentially come in 2026 or 2027. This timeline could shift based on trial readout timing, FDA review priority, and any safety signals. Orforglipron is not available for prescribing outside of clinical trials as of February 2026.
Could orforglipron replace tirzepatide injections?
For efficacy-focused patients, tirzepatide injections will likely remain superior if the Phase 2 weight loss gap (~7–10 percentage points) is confirmed in Phase 3. However, orforglipron could be the preferred first-line option for injection-averse patients, those with needle phobia, elderly patients, or healthcare systems where injectable GLP-1s have poor access. The two drugs may serve complementary roles rather than one replacing the other. Eli Lilly appears to be positioning orforglipron as a companion product to tirzepatide, not a direct replacement.

Explore next